Podcast: This Week in Managed Care—Healthcare on Election Day 2017, and Other Health News

Positive data from the phase 3 EV-302 trial of enfortumab vedotin with pembrolizumab in locally advanced or metastatic urothelial cancer have shifted the landscape.

In this podcast, a trio of experts discuss precision medicine in non–small cell lung cancer (NSCLC), current immunotherapies, and more.

Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.

In part 2 of this 2-part podcast, a panel of experts discusses implementation biosimilars in biologic-naïve patients, auto-substitution, and more.

The US Oncology Network now has more than 2400 providers who treat over 1.4 million patients annually at approximately 600 sites of care in 30 states.

The centers for research are named for Anthony Greco, MD, and John Hainsworth, MD, who founded Sarah Cannon in 1993 as Tennessee Oncology physician researchers.